Hong Kong / Chinese

默克密理博现在是默克

Advance Biotech Grant Program - Taiwan

Unlock your molecule's potential.

Apply to our Taiwan Advance Biotech Grant Program Today!

We understand the challenges biotech companies face in the quest to push their biological drug candidates to market. We are hosting our Advance Biotech Grant Program, the 8th edition, open for Taiwan biotech companies, to help you accelerate to clinic faster.

Apply now for a chance to win free process solution products and services and/or process development services.

Awards

16 000 000 New Taiwan Dollars awarded in awarded in products, services and process development services.

  • First Prize: 4 600 000 New Taiwan Dollars *

  • Second Prize: 1 600 000 New Taiwan Dollars *

  • Third Prize: the "BioReliance End-to-End Prize" : 8 000 000 New Taiwan Dollars **

  • Fourth Prize: the "BioReliance End-to-End Prize" : 1 800 000 New Taiwan Dollars **

* in products and services
** in process development services

How to Apply

Please submit a completed application before 15th August 2019.

Submit Application

Winners will be announced in September 2019.

Official Rules


To learn more on how we can help you accelerate your biotech drug development, watch this testimonial from Kilian Guse, PhD. CEO, Co-Founder GeneQuine Biotherapeutics, and recipient of the 2016 Advance Biotech Grant Program.

Questions? Contact us.

Similar programs will launch in other geographies in the coming months. If you are interested leave your details and we will contact you.

More Info

Application submissions will be judged by a qualified Merck KGaA, Darmstadt, Germany panel of judges, based on the following objective criteria of equal weight: (i) the scientific and societal merit of the therapy being developed, and (ii) process challenges and expertise gaps associated with the development of the therapy. See official program rules for full details. Note. The closing date for submission of Grant applications is midnight on 30th September 2016. Each Application received by midnight on 30th June 2016 will also have the chance to win an iPad tablet. Please refer to the official rules for the Grant and to win an iPad® tablet. Winner selected, informed and announced on or around 15th November 2016.

新兴生物技术，请保持关注

Refresh新兴公司竞赛获奖者于伯林Labiotech宣布

默克集团最近资助了一个表彰新兴生物科技公司的计划。Refresh新兴公司竞赛是新兴生物科技公司向世界展示他们出色想法的一次独一无二的机会，他们所面对的是来自欧洲生物科技界的一流观众。来更多了解一下参赛者，看看谁是赢家吧！ merckmillipore.com/labiotech-2017

详细了解我们的计划：
拨款 | 事件 | 创新 | 协议

将您的分子药物带到市场. 我们致力于满足生命科学领域的需求，作为我们承诺的一部分，我们启动了数个计划来表彰卓越的新兴生物技术公司。这些计划旨在支持新兴生物技术公司和中型公司，帮助他们解决他们目前所面临的生物工艺开发方面的挑战，从而将下一代分子药物带向市场。

详细了解我们的EB计划>

最新网上研讨会：2017年5月11日 - 集成式供应链解决方案加快了ADC开发

详细了解与mAb、偶联子 / 小分子药物供应以及偶联药物服务单一来源合作的优势。

现在观看>

点播网上研讨会

更新：白皮书 - 2017年生命科学高峰论坛

建立与生物技术领域的公开对话.....。

阅读更多并下载>

药物一致性风险

一份默克赞助的经济学人报告。
这份调查报告总结了全球254 位制药专家对制药领域的风险，战略，计划的见解。

阅读研究报告 >

在线

如何让数字化加快初创公司的成长。
下载白皮书，详细了解在线宣传您的新兴公司如何可以增进市场表现。

阅读研究报告 >

重要方面
资金
知识产权
法规
链接
联系我们

研究。开发。生产。

我们是全球生命科学行业领先的供应商：提供在生物技术和药物治疗研究，开发和生产方面的服务和解决方案。

© 2018 默克集团公司（Merck KGaA）版权所有。保留一切权利。
默克密理博是默克集团的组成部分。